Autoantibodies to gangliosides in sera of atherosclerotic patients

Clinica Chimica Acta; International Journal of Clinical Chemistry
N K GolovanovaL D Bergelson

Abstract

Using ELISA we studied the levels and clinical correlation of serum antibodies against gangliosides and 5-hydroxytryptamine (5-HT) in patients with atherosclerosis and clinical manifestations of cardiovascular disease. A range of 70-80% of the patients showed higher titers of anti-GM3(L) and anti-5HT as compared to normal serum. The anti-GM3(L) antibodies appeared to be directed mainly against GM3 present in platelets and were much less reactive against GM3 isolated from the aorta. We concluded that the antigens responsible for the elevated anti-GM3(L) and anti 5-HT levels in atherosclerotic sera are released by vessel-wall activated platelets. These results provide further evidence of on-going autoimmune processes in atherosclerosis. The content of total sialic (TS) and lipid-bound sialic acid (LBS) was measured in sera of patients with IHD and of similar numbers of healthy donors. In the patient groups the average TS and LBS concentration was about 25% higher than in the control group. These changes appeared to be associated with higher degrees of protein sialylation and larger amounts of LDL in the patient sera than in those of healthy controls.

References

Aug 1, 1991·European Journal of Biochemistry·E V DyatlovitskayaL D Bergelson
Oct 1, 1991·Biochimica Et Biophysica Acta·I A MikhailenkoL D Bergelson
May 31, 1991·Biochemical and Biophysical Research Communications·N V ProkazovaL D Bergelson
Dec 15, 1986·Chemistry and Physics of Lipids·S Hakomori
Feb 22, 1988·Biochimica Et Biophysica Acta·A V MazurovL D Bergelson
Sep 1, 1987·European Journal of Biochemistry·N V ProkazovaL D Bergelson
Oct 1, 1972·The Journal of Clinical Investigation·A J MarcusL B Safier
Dec 1, 1984·Agents and Actions·F De ClerckR S Reneman
Jan 1, 1982·Methods in Enzymology·R W Ledeen, R K Yu
Oct 1, 1995·Immunology Today·L D Bergelson
Jan 1, 1995·Immunology Today·G WickQ Xu
Jan 1, 1994·Lipids·N V Prokazova, L D Bergelson
Jun 1, 1993·Clinical Immunology and Immunopathology·R MisasiL Lenti
Jan 1, 1996·Seminars in Nephrology·Z A Massy, W F Keane
Mar 15, 1996·Clinica Chimica Acta; International Journal of Clinical Chemistry·R A Hegele
Dec 31, 1997·Biochimica Et Biophysica Acta·Y V BobryshevN V Prokazova

❮ Previous
Next ❯

Citations

Sep 30, 1999·Environmental Health Perspectives·D A Smith, D R Germolec
Nov 23, 2011·Toxicologic Pathology·Brad Bolon
Dec 29, 2020·Frontiers in Immunology·Seppo Meri, Karita Haapasalo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.